HC
CRDF icon

Hurley Capital’s Cardiff Oncology CRDF Stock Holding History

Hurley Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.4K Sell
2,100
-5,000
-70% -$10.3K ﹤0.01% 510
2025
Q4 		$20K Hold
7,100
– – 0.01% 256
2025
Q3 		$14.6K Buy
+7,100
New +$19.6K 0.01% 318

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Hurley Capital's CRDF Position: Q1 2026 in Review

Hurley Capital reduced its Cardiff Oncology (CRDF) stake by 70% in Q1 2026, selling an estimated $10.3K and leaving 2,100 shares worth $3.4K. The position accounts for ﹤0.01% of the portfolio, ranked #510.

Hurley Capital first reported a position in CRDF in Q3 2025 and has held it in 3 quarters since. The position peaked at $20K in Q4 2025. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Hurley Capital held 2,100 shares of Cardiff Oncology worth $3.4K as of Q1 2026.
  • Hurley Capital sold 5,000 Cardiff Oncology shares in Q1 2026, an estimated $10.3K.
  • Cardiff Oncology made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #510 holding.
  • Hurley Capital first reported a position in Cardiff Oncology in Q3 2025 and has held it in 3 quarters since.
  • Hurley Capital's Cardiff Oncology position peaked at $20K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.